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Abstract
Bordetella pertussis and Bordetella parapertussis are closely related bacterial agents of whooping cough. Whole-cell pertussis (wP) vaccine
was introduced in France in 1959. Acellular pertussis (aP) vaccine was introduced in 1998 as an adolescent booster and was rapidly gen-
eralized to the whole population, changing herd immunity by speciﬁcally targeting the virulence of the bacteria. We performed a tempo-
ral analysis of all French B. pertussis and B. parapertussis isolates collected since 2000 under aP vaccine pressure, using pulsed-ﬁeld gel
electrophoresis (PFGE), genotyping and detection of expression of virulence factors. Particular isolates were selected according to their
different phenotype and PFGE type and their characteristics were analysed using the murine model of respiratory infection and in vitro
cell cytotoxic assay. Since the introduction of the aP vaccines there has been a steady increase in the number of B. pertussis and B. par-
apertussis isolates collected that are lacking expression of pertactin. These isolates seem to be as virulent as those expressing all viru-
lence factors according to animal and cellular models of infection. Whereas wP vaccine-induced immunity led to a monomorphic
population of B. pertussis, aP vaccine-induced immunity enabled the number of circulating B. pertussis and B. parapertussis isolates not
expressing virulence factors to increase, sustaining our previous hypothesis.
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Introduction
The isolation of the aetiological agent of whooping cough,
Bordetella pertussis, allowed the development of whole-cell per-
tussis (wP) vaccines [1]. As early as 1959, wP vaccine was
intensively used in France for primary vaccination of infants at
3–5 months of age and for the ﬁrst booster at 24 months. This
vaccination programme resulted in a dramatic decrease in the
incidence of pertussis among young children but led, during
the next 20 years, to adolescents and adults becoming a new
threat for newborns not yet vaccinated and who required hos-
pitalization after being infected by their elders [2–4]. As a
consequence, in 1995, the French authorities changed the age
of primary vaccination with a wP vaccine to 2 months and the
age for the ﬁrst booster to 16–18 months. Despite the efﬁcacy
of the French wP vaccine, its side effects encouraged the
development of subunit vaccines that were equally efﬁcacious
but devoid of undesirable effects. Acellular pertussis (aP) vac-
cines contain only a few detoxiﬁed bacterial proteins and were
introduced for adolescent booster vaccination in France in
1998 [5]. Use of aP vaccines was rapidly generalized and wP
vaccine was retired from the French market in 2002.
We previously observed that the herd immunity resulting
from wP vaccination had been highly effective in controlling
isolates similar to those used to develop the wP vaccines [6,7].
First genomic analysis showed that the B. pertussis isolates cur-
rently circulating in France have lost genetic material and pos-
sess a higher number of insertion sequence elements [8].
Similar genomic changes have been observed in other Euro-
pean regions [9–12] but not in Bordetella parapertussis isolates
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
[13]. Hence, the generalized use of wP vaccine revealed poly-
morphisms within the B. pertussis population because it was
not able to control all the circulating isolates [13]. The wP vac-
cine-induced herd immunity enabled isolates, as virulent as but
different from the vaccine strains, to emerge [3].
Unlike wP, the aP vaccine includes only a small number of
detoxiﬁed bacterial proteins involved in pathogenicity. All aP
vaccines contain detoxiﬁed pertussis toxin (PT) in addition
to either ﬁlamentous haemagglutinin (FHA); or FHA and
pertactin (PRN); or FHA, PRN and ﬁmbrial proteins 2 and 3
(FIM2 and FIM3) [14]. We have proposed that aP vaccine-
induced immunity would cause the number of circulating
B. pertussis isolates lacking the expression of one or more
vaccine antigens to increase [14]. It was thought that it
should remain ineffective against B. parapertussis [15–17]
although some efﬁcacy of aP vaccine was observed in the
ﬁeld [18]. Since 2005, 7 years after France began using aP
vaccines, surveillance has revealed the appearance of B. per-
tussis and B. parapertussis isolates lacking expression of vac-
cine antigens [19,20].
Here, we ﬁrst analysed all B. pertussis and B. parapertussis
isolates collected since 2000 using pulsed-ﬁeld gel electro-
phoresis (PFGE) and expression of virulence factors. We
show a steady increase in the number of B. pertussis as well
as B. parapertussis isolates lacking expression of PRN. Then,
several isolates belonging to the pre-wP, post-wP or post-aP
vaccine eras were compared using models of in vivo and in
vitro infection.
Materials and Methods
Isolates and growth conditions
Isolates belonging to the pre-vaccine era are part of the collec-
tion of the Institut Pasteur. Since 1993 the National Centre of
Reference of whooping cough and other bordetelloses has been
integrated into our laboratory. The National Centre of Refer-
ence isolated bacteria during epidemiological studies [2,3,21]
and has collected, identiﬁed and archived the bacteria isolated
by microbiologists from 43 paediatric hospitals since 1996 [3].
Hence, 1030 B. pertussis and 49 B. parapertussis isolates were
identiﬁed and analysed since 2000. For murine respiratory infec-
tions and murine macrophage cytotoxicity assays, isolates from
the French pre-wP (5/23), post-wP (4/878) or post-aP (7/1030)
vaccine eras were selected on the basis of the phenotypic and
genetic differences listed in Table 1. Bacteria were grown on
Bordet–Gengou agar (Difco, Franklin Lakes, NJ, USA) supple-
mented with 15% deﬁbrinated sheep blood at 36C for 72 h
and plated again for 24 h before each experiment.
Pulsed-ﬁeld gel electrophoresis
DNA ﬁngerprint by PFGE was performed as previously
described on all isolates [22].
DNA extraction and genotyping
For genotyping, bacterial DNA extractions were performed
using the DNeasy Blood and Tissue Kit (Qiagen, Valencia,
TABLE 1. Characteristics of selected Bordetella pertussis and Bordetella parapertussis isolates
Isolates Year Era Western analysisa FIMb PFGE ptxP prn ptxA RD1 RD2 RD4 LD50 Reference
CIP1672 1950 Pre-vaccine era FHA) (?) 2 II 1 1 1 ) ) + 8 · 107 This study
CIP3077 1950 + 3 II 1 1 4 ) ) + 2 · 107 This study
CIP5456 1953 + 3 II 2 1 4 + + + 1 · 107 This study
Tohama 1954 + 2 II 1 1 2 + + + 8 · 107 [19]
Bp1414 1959 + 2/3 II 1 1 4 + + + 8 · 106 This study
Bp1416 1959 + 3 III 1 1 2 ) ) + 3 · 107 This study
BpHav 1993 wP vaccine era + 3 IVa 1 2 1 ) ) + 3 · 107 This study
FR145 1995 + 3 III 3 1 2 ) ) + 5 · 107 This study
Bp287 1996 + 3 V 1 3 1 ) ) + 8 · 107 This study
Bp743 1999 + 3 IVb 3 2 1 ) ) ) 2 · 108 This study
FR3469 2005 aP vaccine era PT) (?) 3 IVc 3 2 1 ) ) ) NLc This study
FR3693 2007 PRN) (IS) 3 IVa 3 2 1 ) ) ) 6 · 107 [19]
FR3713 2007 + 3 IVc 3 2 1 ) ) ) 2 · 107 This study
FR3749 2007 PT) (D) 3 IVc ) 2 ) ) ) ) NL [19]
FR3793 2007 PRN) (D) 3 IVa 3 2 1 ) ) ) 2 · 108 [19]
FR4615 2009 + 2 IVc 3 2 1 ) ) ) 4 · 107 This study
FR4624 2009 FHA) (?)/PRN) (IS) 3 IVb 3 ) 1 ) ) ) 7 · 107 This study
Bpp 63-2 1963 wP vaccine era + / BppI ND 1.4a-2.9b ND NA NA NA 8 · 107 This study
Bpp 1 1990 + / BppI ND 1.4a-2.9b ND NA NA NA 1 · 108 [20]
Bpp 12822 1993 + / BppI ND 1.4a-2.9b ND NA NA NA 1 · 108 [20]
FR 3728 2007 aP vaccine era PRN) (DG) / BppII ND 1.4a-2.9b ND NA NA NA 1 · 108 [20]
FR 3743 2007 PRN) (DG) / BppII ND 1.4a-2.9b ND NA NA NA 3 · 107 This study
FR4704 2010 PRN) (DG) / BppII ND 1.4a-2.9b ND NA NA NA 5 · 107 This study
AC-Hly, adenylate cyclase haemolysin; aP, acellular pertussis; CIP, Institut Pasteur; FHA, ﬁlamentous haemagglutinin; FIM, ﬁmbrial protein; LD50, median lethal dose; NA, non
applicable; ND, undetermined; PFGE, pulsed-ﬁeld gel electrophoresis; PRN, pertactin; PT, pertussis toxin; RD, region of difference; wP, whole-cell pertussis.
aWestern analyses were conducted using speciﬁc anti-FHA, anti-PRN, anti-PT and anti-AC-Hly antisera. If not speciﬁed, the considered isolate expresses all tested virulence
factors and is designated by +. Question marks (?) are used when reasons of non-expression are unknown. D stands for deletion of the genes and IS for insertion of an Inser-
tion Sequence inside the gene of interest.
bNumbers in the ‘FIM’ column stand for the FIM phenotype: 2 = FIM2, 3 = FIM3 and 2/3 = FIM2 and FIM3.
cNL, non-lethal in the mouse model of respiratory infection. LD50 is given in bacteria by mouse.
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CA, USA) according to the manufacturer’s recommenda-
tions. Genotyping of the repeated regions I and II of the
gene encoding PRN, the S1 subunit of PT and the ptx
promoter (ptxP) were performed as described elsewhere
[23]. A study of genetic evolution of B. pertussis isolates was
also conducted by detection of regions of differences (RD):
RD1 (BP0911–BP0937), RD2 (BP1135–BP1141) and RD4
(BP1948–BP1966) as previously described [8], which were
shown to disappear over time after wP vaccine
introduction.
Western blot analysis
Western blot analyses were performed as described [7]
using speciﬁc antibodies directed against FHA, PRN, PT and
adenylate cyclase haemolysin (AC-Hly) on all isolates since
2000.
Serotyping
FIM2 and FIM3 detection was performed using monoclonal
antibodies as described elsewhere [6].
J774A.1 cell culture and cytotoxicity assays
Culture of the murine monocyte/macrophage-like cell line
J774A.1 (ATCC ref TIB-67) and cytotoxicity assays were
performed as described previously [19].
Murine intranasal model of infection
All procedures involving animals were conducted in accor-
dance with the Institut Pasteur animal care and use commit-
tee guidelines. These experiments were conducted as
described previously [19].
Results
Description of the isolates
The annual number of B. pertussis and B. parapertussis isolates
received since 2000 is shown in Fig. 1. The number of B. par-
apertussis isolates collected remains low compared with the
number of B. pertussis isolates. The interval time-period
between two peaks of pertussis cycles seems to increase
over time. All isolates collected since 2000 possess biochem-
ical characteristics similar to the charactersitics of isolates
collected during the pre-wP and post-wP vaccine eras.
Pulsed-ﬁeld gel electrophoresis
Our previous results showed that B. pertussis isolates col-
lected before the wP vaccination era (before 1959) belonged
to French PFGE groups II and III, which include the French
vaccine strains [7] and were rapidly controlled by wP vac-
cine-induced immunity. In all, 93.8% of all B. pertussis isolates
collected since 2000 belong to PFGE group IV. However,
PFGE group IV subgroups a [7], b [7] and c (this study) were
observed and their proportions evolved following aP intro-
duction (Fig. 2). The B. parapertussis isolates only segregated
into two closely related PFGE groups [20]. Of the B. paraper-
tussis isolates collected since 2007, 71.4% belong to PFGE
group II, ﬁrst identiﬁed in 2007 [20].
Genotyping
Most B. pertussis isolates currently circulating express a type
1 ptxS1 subunit (ptxA1), a type 2 prn and harbour a ptx
operon promoter P3 (ptxP3, Table 1). This promoter type is
FIG. 1. Numbers of Bordetella pertussis
and Bordetella parapertussis isolates anal-
ysed in France since 2000. Annual num-
bers of analysed isolates are
represented for B. pertussis (grey bars)
and B. parapertussis (black bars).
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found in over 90% of all isolates collected since 2000. The
RD genotyping shows that RD1, RD2 and RD4 have been
progressively lost over time and that all isolates collected
since 2000 lack these three regions. Bordetella parapertussis
genotyping indicates that all isolates possess a type 1.4a-2.9b
prn gene.
Virulence factor expression
All B. pertussis isolates collected since 2000 express AC-Hly;
97.2% (1001/1030) express FIM3, 1.3% (13/1030) express
FIM2 and 0.6% (6/1030) express FIM2 and FIM3. Forty iso-
lates collected since 2000 were found not to express one or
more virulence factors. PT), PRN) and PRN) FHA) isolates
account for 5.0% (2/40), 92.5% (37/40) and 2.5% (1/40) of
these collected isolates, respectively. Collection of B. pertus-
sis isolates deﬁcient in PRN expression was sporadic
between 2000 and 2008 but increased since 2009 and their
prevalence reached 13.3% (16/120) of all B. pertussis isolates
collected in 2011 (Fig. 3). The phenotype of the PRN) iso-
lates is mainly the result of the insertion of the IS481 inser-
tion sequence element in region II of the prn gene (51.4%,
19/37). A prn gene deletion (2.7%, 1/37), a 25-nucleotide
deletion in the ﬁrst repeated region (2.7%, 1/37), an 89-
nucleotide deletion at the 5¢ end of the prn gene (2.7%, 1/
37) or a mutation leading to a stop codon at position 1479
of the prn gene (2.7%, 1/37) was also found in isolates with
such a phenotype. The PT) phenotype is due to the deletion
of the entire ptx operon in one isolate but further analyses
are needed to understand this phenotype in the other isolate
and to understand the FHA) phenotype. The PRN) B. par-
apertussis was ﬁrst isolated in 2004, but since 2007, 94.3%
(32/35) of all collected B. parapertussis isolates have been
PRN). This phenotype is caused by the deletion of an A in
region I of the prn gene (position 988, 12.1%, 4/33) or a G in
region II (position 1895, 75.8%, 25/33) both of which lead to
a stop codon.
Macrophage cytotoxicity
All selected B. pertussis isolates were cytotoxic for murine
macrophages whereas none of the B. parapertussis isolates
tested were cytotoxic (data not shown).
Murine model of respiratory infection
All selected isolates, except the two PT) ([19] and this
study), were lethal to mice, including the PRN), FHA) and
PRN) FHA) isolates, and exhibited similar median lethal
dose (LD50) values (Table 1). Isolates harbouring a ptxP3
promoter type supposed to express more PT are not more
virulent. The B. parapertussis isolates exhibit similar LD50
(Table 1) whether they express PRN or not ([20] and this
study).
Discussion
In the present study we show that since the introduction of
aP vaccines in France, 93.8% of the isolates collected are part
of the same PFGE group IV, which can be divided in three
subgroups, a [7], b [7] and c (which appeared in 2004, this
study). Distributions within these subgroups seem to have
reached equilibrium because no major changes have been
observed since 2005. Although wP vaccine-induced immunity,
which targets the whole bacterium, effectively controlled cir-
culating isolates resembling vaccine strains in France, i.e. iso-
lates belonging to PFGE groups II and III [6,7,12], it did not
control PFGE group IV isolates [6,7]. The aP vaccine-induced
immunity therefore maintained the monomorphic population
of B. pertussis observed after the use of wP vaccine despite
FIG. 2. Evolution of the proportion of
French Bordetella pertussis pulsed-ﬁeld
gel electrophoresis (PFGE) group IV
subgroups. Acellular pertussis (aP) vacci-
nation was ﬁrst introduced in France in
1998 as an adolescent booster before
being generalized to the whole popula-
tion in 2000. Since 2000, 94% of all the
B. pertussis isolates analysed are part of
PFGE group IV. This PFGE group can be
subdivided in three subgroups, for which
the annual proportions are shown on
this ﬁgure.
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the emergence of the PFGE group IV c subgroup. However,
emergence of a new PFGE group was observed within the
B. parapertussis population in 2007 [20] and 71.4% of all
B. parapertussis isolates collected since then are part of this
new group.
Along with evolutionary changes in PFGE group distribu-
tion after wP vaccine introduction, particular genomic
regions have shown evidence of evolution as well. In addition
to changes previously detected in the ptxS1 subunit (ptxA1
replaced ptxA2 and ptxA4 alleles) and the PRN structural
gene (prn2 replaced prn1 allele), it was reported that the
promoter of the ptx operon has evolved towards a ptxP3
type promoter since the late 1980s [23]. Similar evolutions
were observed in France [7,8] and in other European coun-
tries [10,12,13] after wP vaccine introduction. It has to be
noted that although all isolates harbouring a ptx P3 type pro-
moter are suggested to express more PT [23], they are not
more virulent in the murine respiratory model.
It was hypothesized that the B. pertussis population could
cope with aP-induced immunity by losing the expression of
vaccine antigens [14], by gaining expression of new antigens
or by overexpressing antigens not included in aP vaccines
such as AC-Hly, because clinical isolates presenting cyaA
gene duplication were already described [24].
By controlling expression of virulence factors by collected
isolates we recorded a steady increase in the number of iso-
lates not expressing PRN since 2007, 7 years after general-
ization of aP vaccination in France. They represent 7.8% (32/
408) of all isolates collected since 2007 and their proportion
reached 13.3% (16/120) in 2011. It is important to note that
these data rely on annual surveillance and not on isolates
collected during an outbreak of pertussis [3]. Although PT),
FHA) or PRN) isolates were collected during the pre-vac-
cine and post-vaccine eras in France and in Italy ([25] and
this study), they did not expand like PRN) isolates have
since 2007. This expansion does not appear to be clonal
because the PRN) phenotype can result from different geno-
mic events. Although PRN was thought to be a major B. per-
tussis adhesin, its loss does not seem to hinder lethality or
transmission. PRN) isolates exhibit LD50 values similar to
those of PRN+ isolates in the respiratory murine model and
retain their ability to be transmitted in the human population
(H. Bodilis and N. Guiso, unpublished data). A possible
explanation for this phenotype might be found in the great
diversity of auto-transporter proteins found in B. pertussis,
which may compensate for the loss of PRN expression [26].
Currently, the other well-known virulence factors, targeted
or not by aP vaccine-induced immunity, do not seem to be
affected. All isolates still express AC-Hly, which is not part
of the aP vaccines. As a consequence of the universal expres-
sion of this toxin, all selected isolates for this study were
cytotoxic for murine J774A.1 macrophages as expected [27].
Even though variable, no increase in this toxin expression, as
measured by adenylate cyclase activity, was observed over
time (data not shown).
One could speculate that the loss of PRN expression
could be the result of host adaptation because B. pertussis
recently emerged from B. bronchiseptica [28] and might still
undergo genetic rearrangements. Even though loss of genetic
material through RD elimination or gain in genome plasticity
through increase in insertion sequence element numbers [8]
could ﬁt host adaptation, strong evidence for aP vaccine-
driven loss of PRN expression can be found. Indeed, it was
recently published that in Japan, a country using aP vaccines
since the 1980s, circulation of PRN) isolates has been
observed since 2000 [29]. Even though it is too soon to
assume that our hypothesis is veriﬁed, other countries using
aP vaccines should survey virulence factor expression of
circulating isolates to verify if they encounter such a phe-
nomenon.
FIG. 3. Evolution of the proportion of
Bordetella pertussis isolates not express-
ing pertactin (PRN) since 2000. Detec-
tion of PRN expression was performed
using Western blot analysis and speciﬁc
anti-PRN antiserum. No PRN B. pertussis
isolates were collected before 2003.
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Another point of interest is the evolution of the B. par-
apertussis population. Since 2007, 71.4% of the isolates are
part of a new PFGE group ([20] and this study). Further-
more, 94.2% (33/35) of the B. parapertussis isolates collected
since 2007 are PRN) and this phenomenon does not seem
to be related to PFGE group distribution. The lack of
expression of PRN is the consequence of different genetic
events, indicating that these isolates did not arise from the
same ancestor. As observed with B. pertussis PRN) isolates,
B. parapertussis PRN) isolates exhibit LD50 values similar to
their PRN+ counterparts.
As shown previously, wP vaccine-induced immunity does
not seem to protect against B. parapertussis in the ﬁeld
[13,18]. However, whereas aP vaccine-induced immunity was
hypothesized to be ineffective against B. parapertussis [16] in
the ﬁeld, an observation conﬁrmed in an animal model of
infection [15,17], another study performed during a clinical
trial comparing wP and aP vaccines suggested that aP vacci-
nation might be effective in controlling B. parapertussis [18].
It is therefore tempting to assign the emergence of PRN)
B. parapertussis isolates to aP herd immunity.
In conclusion, even though genetic rearrangements took
place in the absence of human interference [28], human vac-
cination strategies introduced a new challenge that bacterial
populations had to overcome, promoting evolution and
selection among these populations. It is clearly known now
that in France, wP vaccination favoured genotypic changes
(PFGE IV, ptxP3, prn2, ptxA1) in the B. pertussis population
[6,7], changes which could not be observed in regions of low
vaccine coverage (Senegal) [21]. Gene loss (RDs) and
increase in insertion sequence elements are also part of the
adaptation of the B. pertussis population to its host. Whether
they are inﬂuenced by vaccination should be appreciated in
regions with no or very low vaccine coverage. Continuous
surveillance for antigenic change in B. pertussis and B. paraper-
tussis strains is therefore required as a tool for monitoring
pertussis vaccine effectiveness.
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